Unknown

Dataset Information

0

Antiviral drugs for coronavirus disease 2019 (COVID-19): a systematic review with network meta-analysis.


ABSTRACT:

Background

To better inform clinical practice, we summarized the findings from randomized controlled trials (RCTs) of antivirals for COVID-19.

Methods

We systematically searched for literature up to September 2020, and included English-language publications of RCTs among hospitalized COVID-19 patients. We conducted network meta-analysis combining results of both the direct and indirect comparisons of interventions. The efficacy outcomes were clinical progression, all-cause mortality, and viral clearance, and safety outcomes were diarrhea, nausea, and vomiting. We generated treatment rankings (best to worst) and summarized rank probabilities using rankogram.

Results

We included 15 RCTs (14,418 patients) from 7,237 retrieved citations. There was no evidence for efficacy of the assessed antivirals compared with placebo/no treatment or with another antiviral for all efficacy outcomes. Lopinavir (400 mg)/ritonavir (100 mg) significantly increased diarrhea, nausea, and vomiting compared with placebo/no treatment and other antivirals, and was ranked worst for these outcomes, while triazavirin (250 mg), baloxavir marboxil (80 mg), and remdesivir (100 mg - 10 days) ranked best, respectively.

Conclusions and relevance

The available evidence does not support the use of any antiviral drugs for COVID-19. Cautious interpretations of the findings are, however, advised considering the paucity of the evidence. More RCTs are needed for a stronger evidence base.

SUBMITTER: Okoli GN 

PROVIDER: S-EPMC8477589 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Antiviral drugs for coronavirus disease 2019 (COVID-19): a systematic review with network meta-analysis.

Okoli George N GN   Rabbani Rasheda R   Al-Juboori Amenah A   Copstein Leslie L   Askin Nicole N   Abou-Setta Ahmed M AM  

Expert review of anti-infective therapy 20210817 2


<h4>Background</h4>To better inform clinical practice, we summarized the findings from randomized controlled trials (RCTs) of antivirals for COVID-19.<h4>Methods</h4>We systematically searched for literature up to September 2020, and included English-language publications of RCTs among hospitalized COVID-19 patients. We conducted network meta-analysis combining results of both the direct and indirect comparisons of interventions. The efficacy outcomes were clinical progression, all-cause mortali  ...[more]

Similar Datasets

| S-EPMC7245646 | biostudies-literature
| S-EPMC7273516 | biostudies-literature
| S-EPMC7595919 | biostudies-literature
| S-EPMC7436402 | biostudies-literature
| S-EPMC7643964 | biostudies-literature
| S-EPMC8127467 | biostudies-literature
| S-EPMC7385501 | biostudies-literature
| S-EPMC9328465 | biostudies-literature
| S-EPMC8989131 | biostudies-literature
2022-04-08 | GSE178246 | GEO